Phibro Animal Health Corp at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. Thank you for dialing in. My name is Balaji Prasad. I cover specialty pharma for Barclays. This is a continuation of our virtual healthcare conference. And for the session now, we have with us today the senior management team of Phibro. We have Richard Johnson, CFO; and Donny -- Daniel Bendheim, Senior Vice President -- Executive -- Corporate Strategy. Also, reminder that owing to the nature of this format, there will be no Q&A session at the end of this.
Richard and Donny, thank you for joining us. Would you like to start with an overview and then outlook of how you're seeing the business evolve? And we have a few questions that we can launch into post your overview. Thank you.
Right. Let me first give a brief overview, and I'll probably just summarize our numbers and our guidance that's out there for the year.
We are a roughly $800 million, a little north of $800 million annual revenue
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
